PRTN3 and rheumatoid arthritis: Many efforts have been made to resolve these issues; for example, the EULAR Task Force has suggested that, when measuring CV risk in RA patients, risk models should be adjusted by adding a multiplication factor of 1.5 when a patient fits two or more of the following three criteria: (a) positive for anti-citrullinated protein antibodies (ACPA) or rheumatoid factor, (b) duration of the disease is over 10 years, and (c) occurrence of extra-articular manifestations [19].